Can Bristol-Myers Squibb Recover?
The beaten-down shares of this high-quality pharmaceutical company should rebound with the economy.
Bristol-Myers Squibb doesn't have a pill to make shareholders feel better for the 30%-plus hit their stock has taken since peaking at $32 last July -- or, for that matter, for the 71% plunge since early 2001.
If you need a little pick-me-up for your portfolio, though, consider buying Bristol shares today. The stock (symbol BMY) is washed-out, suggesting little downside risk from current levels and, if a few things go right, the shares could gain 25% over the coming year.
But first, why the big drop? Bristol-Myers is in good company, having slid along with most of the other drug makers that are collectively known as big pharma. The two big concerns: Many major patents are due to expire in coming years, and a tighter regulatory environment will create a "revolutionary change" in the industry, says Credit Suisse analyst Catherine Arnold.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
She says the Food and Drug Administration will ratchet up scrutiny in the coming months, and the election of a Democratic president would put pressure on drug prices. Plans of both Hillary Clinton and Barak Obama include allowing Medicare to negotiate drug prices, which would effectively regulate pill prices, and permitting drugs that carry lower price tags in foreign countries to be re-imported to the U.S.
But Bristol is really cheap, much cheaper than I think this high-quality, profitable company deserves to be. At its March 28 close of $21.48, the stock is near both a 52-week and a five-year low.
Another pillar that should prop up the stock is its lush yield. Based on the annual cash dividend of $1.24 per share, which I think is secure, the stock yields 5.8%.
As for profits, analysts expect Bristol to earn $1.69 a share in 2008. That's a 14% increase over last year's earnings and compares with a 10% average earnings increase for the drug industry sector. Earnings "growth at rates near the top of big-pharma and a very attractive valuation" -- 13 times estimated '08 profits -- recently prompted Zacks Equity Research to bump up its rating on Bristol from hold to buy.
Earnings growth a few years down the line is a little shaky, though. The Zacks analysts, Brian Marckx and Jason Napodao say current earnings are driven by the "mega-blockbuster" drug Plavix, which helps prevent heart attack and stroke. However, they point out, the Plavix patent expires in 2011. Unlike some other drug companies, though, Bristol's pipeline contains some promising new drugs, which could fill the gap once Plavix generics start flooding the market.
But there's a big kicker. Given Bristol's low price, the Zacks analysts think the company is an attractive takeover candidate for even bigger drug companies, such as Sanofi or Pfizer.
Maybe. But if that doesn't happen, you can comfort yourself by collecting those fat dividends and watching the stock rise when the market rebounds.
To continue reading this article
please register for free
This is different from signing in to your print subscription
Why am I seeing this? Find out more here
-
A Letter of Wishes: No Legal Power But Powerful Nonetheless
A letter of wishes lets you explain, in plain language, your intent behind your estate documents, potentially heading off any misunderstandings or disputes.
By Steve Lockshin Published
-
$1,500 to $3,000 Amex Card Intro Offer
Amex intro offer worth $1,500 to $3,000 provides new Business Platinum cardholders 150,000 membership points.
By Ellen Kennedy Published
-
Stock Market Today: Markets Post Broad-Based Gains Thanks to Mega-Cap Tech
Stocks get help from a couple of laggard Magnificent 7 stocks.
By Dan Burrows Published
-
Stock Market Today: Markets Soar Amid Strong Earnings for Big Tech
Equities ended the week on an up note thanks to some of the market's biggest names.
By Dan Burrows Published
-
Stock Market Today: Markets Tumble Amid Slower Economic Growth and Rising Prices
Disappointing readings on GDP and inflation helped tank equities.
By Dan Burrows Published
-
Stock Market Today: Stocks Run Out of Steam Ahead of Meta Earnings
The Dow Jones Industrial Average snapped a four-day winning streak after Boeing's first-quarter results.
By Karee Venema Published
-
Stock Market Today: Nasdaq Soars Ahead of Tesla Earnings
The EV stock rose nearly 2% ahead of its highly anticipated Q1 earnings report, due after tonight's close.
By Karee Venema Published
-
Stock Market Today: Markets Rebound Ahead of Big Week for Earnings
Equities rallied on easing geopolitical tensions, upcoming quarterly results.
By Dan Burrows Published
-
Stock Market Today: Nasdaq Spirals as Netflix Nosedives
A big earnings boom for credit card giant American Express helped the Dow notch another win.
By Karee Venema Published
-
Stock Market Today: S&P 500, Nasdaq Extend Losing Streaks
The two indexes have closed lower for five straight sessions.
By Karee Venema Published